Use of a peptide as a therapeutic agent

Details for Australian Patent Application No. 2008303896 (hide)

Owner mondoBIOTECH Laboratories AG

Inventors Bacher, Gerald; Cavalli, Vera; Bevec, Dorian; Cavalli, Fabio

Agent Spruson & Ferguson

Pub. Number AU-A-2008303896

PCT Pub. Number WO2009/040032

Priority 07017762.1 11.09.07 EP

Filing date 9 September 2008

Wipo publication date 2 April 2009

International Classifications

A61K 38/17 (2006.01) Medicinal preparations containing peptides - from animals

A61K 38/35 (2006.01) Medicinal preparations containing peptides

A61P 3/00 (2006.01) Drugs for disorders of the metabolism

A61P 9/00 (2006.01) Drugs for disorders of the cardiovascular system

A61P 11/00 (2006.01) Drugs for disorders of the respiratory system

A61P 25/28 (2006.01) Drugs for disorders of the nervous system

A61P 31/00 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A61P 35/00 (2006.01) Antineoplastic agents

A61P 37/00 (2006.01) Drugs for immunological or allergic disorders

Event Publications

22 April 2010 PCT application entered the National Phase

  PCT publication WO2009/040032 Priority application(s): WO2009/040032

20 September 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008303900-Use of a galanin peptide as a therapeutic agent

2008303893-Use of adrenomedullin as a therapeutic agent for the treatment of excessive angiogenesis